Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant ADT + Abiraterone +/- Apalutamide in High-Risk Prostate Cancer
NCT02789878Phase 2Completed
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Jan 2019
- Primary completion
- Apr 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Instituto do Câncer do Estado de São Paulo. Primary endpoint: Pathologic Response at 3 months. Started Jan 2019; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02789878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02789878.